middle.news
Acrux Advances Female Testosterone Phase III Trials with Revenue Surge and Funding Plans
6:24pm on Thursday 30th of April, 2026 AEST
•
Healthcare
Read Story
Acrux Advances Female Testosterone Phase III Trials with Revenue Surge and Funding Plans
6:24pm on Thursday 30th of April, 2026 AEST
Key Points
March quarter revenue rises to $0.552 million
FDA clears path for Phase III female testosterone trial
Operating costs decline with R&D reprioritisation
Cash reserves at $586k with 1.2 quarters funding
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Acrux (ASX:ACR)
OPEN ARTICLE